Background-Endothelial damage and dysfunction are crucial mediators that link diabetes mellitus with atherosclerotic cardiovascular disease. AMP-activated kinase (AMPK) has been implicated in regulation of both energy metabolism and vascular homeostasis. The present study investigated whether endothelium-selective activation of AMPK prevents diabetes mellitus-induced endothelial damage and vascular dysfunction by improving reendothelialization in mice. Methods and Results-Transgenic mice with endothelium-selective expression of a constitutively active (CA) AMPK were generated and rendered diabetic by the injection of streptozotocin. Relaxation and reendothelialization of carotid arteries and circulating numbers of endothelial progenitor cells (EPCs) were examined after wire-induced denudation. Bone marrow-derived EPCs were isolated to monitor their in vivo and in vitro function. Compared with wild-type littermates, the CA-AMPK transgenic mice were resistant to diabetes mellitus-induced impairment in endotheliumdependent relaxation and reendothelialization of their injured carotid arteries. These changes in the transgenic mice were accompanied by increased mobilization of EPCs and enhanced incorporation of EPCs into injured blood vessels. Furthermore, EPCs from the transgenic mice exhibited augmented adhesion, migration, and tube formation capacities. At the molecular level, the expression of heme oxygenase (HO)-1 and the secretion of stromal cell-derived factor (SDF)-1␣ were upregulated in EPCs derived from the transgenic mice, whereas AMPK-mediated elevation of serum SDF-1␣ levels and improvements of EPC function and reendothelialization were all abrogated by pharmacological inhibition of heme oxygenase-1.
the onset and progression of cardiovascular complications in diabetic patients. 1, 2 Under physiological conditions, endothelial repair is accomplished through contribution of endothelial progenitor cells (EPCs). 3, 4 In response to vascular damage, EPCs are mobilized from bone marrow into the circulation and subsequently migrate to the area of injury to facilitate reendothelialization. 4 This process is regulated by proangiogenic factors, including stromal cell-derived factor (SDF)-1␣ 5 and vascular endothelial growth factor (VEGF). 6 EPCs per se secrete proangiogenic growth factors and cytokines that induce neovascularization by promoting the migra-tion and proliferation of local endothelial cells. 7 Diabetic vascular complications may be in part caused by the inability
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of EPCs to exert their reparative function. 8 In both diabetic patients and animals, the number of circulating EPCs is reduced. 8, 9 In addition, diabetic EPCs exhibit diminished functionality, including decreased migration/homing prowess, reduced proliferative capacity, and altered secretory profiles of cytokines and growth factors. 10, 11 Transfusion of EPCs can alleviate endothelial dysfunction and atherosclerosis in various animal models, 12, 13 which high-lights the therapeutic potential of EPCs in the treatment of vascular diseases.
AMP-activated protein kinase (AMPK) is an energy sensor that controls whole-body glucose and lipid homeostasis by direct phosphorylation of its target proteins and by modulating gene expression. 14 Besides its pleiotropic salutary effects on energy metabolism and insulin sensitivity, AMPK is also an important regulator of vascular homeostasis. 15 Many agents and factors with cardiovascular benefits, including statins, metformin, fenofibrate, estradiol, ␣-lipoic acid, highdensity lipoprotein, adiponectin, and VEGF, have been shown to induce AMPK activation in endothelial cells. 12, 15 Activation of AMPK in endothelial cells by these vasculoprotective agents trigger several biological effects beneficial to vascular homeostasis, including augmentation of nitric oxide production through endothelial nitric oxide synthase, 16 suppression of hyperglycemia-induced generation of reactive oxygen species, 17 alleviation of free fatty acids-induced lipotoxicity, 18 inhibition of nuclear factor-B activation by tumor necrosis factor-␣, 19 and protection against apoptosis. 20 Furthermore, pharmacological activation of AMPK enhances the functionality of cultured EPCs, including tube formation, migration, adhesion, and differentiation. 21, 22 Despite these promising findings, the physiological roles of AMPK in the regulation of endothelial repair and vascular function remain poorly characterized. Therefore, the objectives of the present study were to generate transgenic mice with endothelium-specific expression of a constitutively active (CA)-AMPK to investigate whether endotheliumselective AMPK activation is sufficient to prevent diabetes mellitus-induced impairment in endothelium-dependent relaxation and in vascular repair after injury and to further delineate the molecular basis whereby AMPK mediates endothelial regeneration in mice.
Methods
An expanded Methods section is available in the online-only Data Supplement.
Generation of CA-AMPK Transgenic Mice
The transgenic founders were generated by microinjection of the cDNA encoding c-myc-tagged CA-AMPK ␣1-subunit under the transcriptional control of a 2.5-kb vascular endothelial-cadherin promoter into the pronucleus of fertilized eggs of C57BL/6ϫCBA mice, followed by backcrossing with C57BL/6J for at least 6 generations. All experimental protocols were approved by the Committee on the Use of Live Animals in Teaching and Research at the University of Hong Kong.
Reendothelialization Assay
Wire-induced carotid denudation was performed in 12-week-old CA-AMPK transgenic mice or wild-type (WT) littermates as described previously. 23 On various days after carotid injury, reendothelialization was assessed by Evans blue staining. The stained and unstained areas were quantified with National Institutes of Health ImageJ software.
Isometric Tension Measurements
The arterial rings of carotid or mesenteric arteries from CA-AMPK transgenic mice or WT littermates were mounted in wire myographs and equilibrated for 60 minutes under 0.5g tension. Afterward, the rings were contracted with phenylephrine (1 mol/L), followed by cumulative concentrations of acetylcholine, UK14304, or sodium nitroprusside for measurement of endothelium-dependent and -independent relaxations.
Transplantation of Bone Marrow-Derived EPCs
EPCs were isolated from donor mice by use of a magnetic cellsorting system with a lineage deletion kit as described previously 23 and prestained with acetylated low-density lipoprotein labeled with DiI (DiI-AcLDL), followed by infusion into recipient mice that had undergone carotid injury and ␥-irradiation. Three days after recovery, injured carotid arteries were fixed, dissected longitudinally, and assessed under fluorescent microscopy to determine the number of prelabeled EPCs incorporated into the blood vessel wall.
Statistical Analyses
All data presented are raw values and are expressed as meanϮSEM. The relaxation responses to various agonists are expressed as the percentage of the initial precontraction with 1 mol/L phenylephrine. An individual dose-response curve was fit to a sigmoidal logistic equation by nonlinear regression to calculate pEC50 (Ϫlog concentrations at which agonists cause 50% of the maximal response [R max ]). One-way ANOVA was used for comparison between 2 groups and for 3 pairwise comparisons between each pair of the 3 groups without Bonferroni correction. For the experiments that involved 2 or 3 factors, data were analyzed by 2-or 3-way ANOVA, respectively, followed by Bonferroni post hoc tests, and all probability values were Bonferroni-adjusted across all possible comparisons. Statistical analyses were performed with GraphPad Prism version 5.0.
Results

Generation of Transgenic Mice With Endothelium-Specific Expression of CA-AMPK
To investigate the effects of AMPK activation on vascular function, we generated a construct for transgenic expression of a c-myc epitope-tagged constitutively active form of AMPK ␣-subunit (CA-AMPK) in which the autoinhibitory site is removed ( Figure 1A ). 24 The CA-AMPK gene is under the control of a 2.5-kb vascular endothelial-cadherin promoter, which drives endothelium-specific expression. 25 The linearized transgenic construct was introduced into pronuclei of fertilized eggs of C57BL/6ϫCBA mice, and transgenic founders were identified by genotyping ( Figure 1B ). Western blot analysis detected a high level of myc-tagged CA-AMPK expression in aortic tissues and bone marrow-derived EPCs isolated from CA-AMPK transgenic mice, which was accompanied by increased phosphorylation of acetyl-CoA carboxylase, a downstream target of AMPK ( Figure 1C ). The expression of myc-tagged CA-AMPK was only detected in intact carotid arteries from CA-AMPK transgenic mice, not in WT mice or in denuded vessels ( Figure 1D ). Furthermore, CA-AMPK transgenic mice displayed higher AMPK activity in both aortas and carotid arteries than WT mice ( Figure 1E ).
CA-AMPK Transgenic Mice Exhibit Improved Endothelium-Dependent Vasodilation and Vascular Repair After Carotid Injury
Relaxations to acetylcholine were comparable in carotid arteries of healthy CA-AMPK transgenic and WT mice ( Figure 2A ). Carotid arteries collected 7 days after wireinduced injury exhibited a significantly decreased sensitivity to acetylcholine in both WT mice ( Figure 2B When mice were injected with streptozotocin to induce diabetes mellitus, there was no obvious difference in hyperglycemia or body weight between the CA-AMPK transgenic and WT groups (online-only Data Supplement Figure I ). Streptozotocin-induced diabetes mellitus led to a modest decrease in the sensitivity of carotid arteries to acetylcholine in WT mice ( Figure 2D ) but not in CA-AMPK transgenic mice ( Figure 2E ). Both the sensitivity and maximal response of small mesenteric resistance arteries to acetylcholine in diabetic WT mice were markedly reduced compared with healthy WT mice, whereas such diabetes-induced impairment was less obvious in CA-AMPK transgenic mice compared with diabetic WT mice (online-only Data Supplement Figure II) .
When diabetic WT mice were subjected to wire-induced carotid injury followed by 7 days of recovery, both the sensitivity and maximal response of carotid arteries to acetylcholine were significantly diminished compared with those in diabetic WT mice without injury ( Figure 2F ; pEC50 7.40Ϯ0.26 in WTϩstreptozotocinϩinjury versus 8.12Ϯ0.11 in WTϩstreptozotocin, PϽ0.01; R max 82.49Ϯ5.48% in WTϩ streptozotocinϩinjury versus 93.71Ϯ6.23% in WTϩ streptozotocin, PϽ0.05; nϭ6). However, this impairment in relaxations in injured carotid arteries of diabetic CA-AMPK transgenic mice was less obvious than for those in diabetic WT controls (pEC50 8.31Ϯ0.1 in transgenicϩstreptozotocinϩ injury versus 7.40Ϯ0.26 in WTϩstreptozotocinϩinjury, PϽ0.01; R max 93.60Ϯ4.27% in transgenicϩstreptozotocinϩ injury versus 82.49Ϯ5.48% in WTϩstreptozotocinϩinjury, PϽ0.01; nϭ6).
The carotid arteries of CA-AMPK transgenic mice showed a slightly higher sensitivity to UK14304 (an agonist at ␣2-adrenergic receptors 26 ) than those of WT mice (onlineonly Data Supplement Figure IIIA; pEC50 6.18Ϯ0.25 in transgenic versus 5.80Ϯ0.19 in WT, PϽ0.05; nϭ6). In carotid arteries isolated from WT mice 7 days after wireinduced injury, the relaxation to UK14304 was significantly impaired compared with uninjured controls (online-only Data Supplement Figure IIIB; pEC50 4.38Ϯ0.57 in WTϩinjury versus 5.80Ϯ0.19 in WT, PϽ0.01; R max 54.66Ϯ9.54% in WTϩinjury versus 75.83Ϯ4.96% in WT, PϽ0.05; nϭ6), whereas such wire-induced impairment was less obvious in CA-AMPK transgenic mice (pEC50 5.56Ϯ0.07 in transgenicϩ injury versus 4.38Ϯ0.57 in WTϩinjury, PϽ0.05; R max 81.1Ϯ0.21% in transgenicϩinjury versus 54.66Ϯ9.54% WTϩ injury, PϽ0.05; nϭ6). Furthermore, diabetes mellitus-induced impairment of relaxation to UK14304 in carotid arteries of CA-AMPK transgenic mice was significantly attenuated in both uninjured conditions (online-only Data Supplement Figure To investigate whether the augmented vasodilation in injured carotid arteries of CA-AMPK transgenic mice was attributable to accelerated vascular repair, the blood vessels were subjected to Evans blue staining. On day 1 after carotid injury, there was no obvious difference in the magnitude of endothelial damage between CA-AMPK transgenic mice and WT controls ( Figure 3A and 3B). In WT mice, 42.2% of the denuded areas were reendothelialized on day 3 after injury. Compared with healthy WT controls, reendothelialization was impaired in diabetic WT mice ( Figure 3B ). By contrast, transgenic expression of CA-AMPK increased reendothelialization in healthy mice and reversed diabetes mellitusinduced impairment in reendothelialization. A similar trend of enhanced reendothelialization in CA-AMPK transgenic mice was also observed on day 5 after carotid injury (data not shown).
Transgenic Expression of CA-AMPK Prevents Diabetes Mellitus-Induced EPC Dysfunction
Because EPCs are an important contributor to endothelial repair, 3, 4 the circulating number of EPCs was monitored by flow cytometry analysis with antibodies against the 2 cell surface markers of EPCs (Flk1 and CD34). 27 In healthy WT mice, there was a 10.75-fold elevation in the number of circulating EPCs on day 3 after carotid injury compared with uninjured controls ( Figure 4A and 4B). This carotid injuryinduced EPC elevation was substantially reduced in diabetic WT mice compared with healthy controls, which confirms impaired EPC mobilization in diabetes mellitus. The increase in the number of circulating EPCs in CA-AMPK transgenic mice after carotid injury was higher than in WT controls, and such a change became more obvious under diabetic condition ( Figure 4 ). Likewise, carotid injury induced a significant elevation in the number of circulating angiogenic cells (CD31 ϩ CXCR4 ϩ ) in healthy WT mice, whereas such an increase was impaired by streptozotocin-induced diabetes mellitus (online-only Data Supplement Figure IV ). Under both healthy and diabetic conditions, the number of circulating angiogenic cells in CA-MAPK transgenic mice was higher than in WT littermates.
To further investigate the effects of AMPK activation in EPCs, Lin Ϫ c-Kit ϩ Flk-1 ϩ cells were isolated from bone marrow-derived mononuclear cells by a magnetic cellsorting system. 23 Fluorescence-activated cell sorter analysis showed that these cells were positively stained with CD31, CD34, CD117 (cKit), and Flk1 but negatively stained with CD45 and CD115 (online-only Data Supplement Figure VA) , which are characteristic features of EPCs. 27 The isolated cells Bone marrow transplantation was performed next to monitor the incorporation of EPCs into the injured blood vessel wall. The recipient mice were subjected to carotid injury and subsequent irradiation to deplete endogenous EPCs, followed by intravenous injection of exogenous EPCs prelabeled with red fluorescent dye (DiI). With fluorescence microscopic analysis, the incorporation of DiI-stained cells into the injured arteries of the recipient mice was detected 3 days after recovery from injury ( Figure 5A ). When EPCs from healthy WT donors were transplanted into either healthy WT or CA-AMPK transgenic mice, a similar number of attached fluorescent cells were observed between the 2 types of recipients (data not shown). On the other hand, healthy WT recipient mice receiving EPCs isolated from CA-AMPK transgenic mice displayed a modest but statistically insignificant increase in the number of attached fluorescent cells compared with those receiving EPCs from WT controls ( Figure 5B ). Notably, EPCs isolated from diabetic WT mice exhibited significant impairment in incorporation into injured carotid arteries, whereas the attachment capacity of EPCs isolated from diabetic CA-AMPK transgenic mice was comparable to that of EPCs from healthy WT or CA-AMPK transgenic mice ( Figure 5B ), which suggests that AMPK activation reverses diabetes mellitus-induced impairment in EPC function. The incorporation of EPCs from healthy CA-AMPK transgenic mice into diabetic WT recipients was enhanced compared with EPCs from WT controls (onlineonly Data Supplement Figure VIA) ; however, there was no obvious difference in incorporation of healthy WT EPCs into diabetic transgenic mice and WT mice. Further analysis by immunostaining revealed that the incorporated DiI-positive EPCs in both WT and CA-AMPK transgenic mice did not overlap with the in situ proliferative (Ki67 ϩ ) endothelial cells in the injured endothelial layer (online-only Data Supplement Figure VIB) .
In vitro functional assays demonstrated that adhesion of EPCs from healthy CA-AMPK transgenic mice was enhanced compared with those from healthy WT controls ( Figure 6A ), whereas the difference in migration and tube formation did not reach statistical significance between the 2 groups ( Figure 6B and 6C ). EPCs from diabetic WT mice but not from diabetic CA-AMPK transgenic mice exhibited impaired capacity for adhesion, migration, and tube formation ( Figure 6A through 6C ). Furthermore, superoxide levels in EPCs ( Figure 6D ) and carotid arteries ( Figure 6E ) in both healthy and diabetic CA-AMPK transgenic mice were lower than in healthy and diabetic WT mice.
AMPK Activation Improves EPC Function by Inducing Heme Oxygenase-1 and SDF-1␣
Heme oxygenase (HO)-1 is an antioxidant protein implicated in the regulation of EPC function 28, 29 and vascular repair. 30 Because AMPK activation promotes the expression and activity of HO-1, 31 we tested the hypothesis that enhanced EPC mobilization and functions in CA-AMPK transgenic mice are attributed to induction of HO-1. Immunoblotting analysis detected a higher level of HO-1 protein expression in EPCs of CA-AMPK transgenic than WT mice ( Figure 7A ). Furthermore, streptozotocin-induced diabetes mellitus caused a marked reduction in HO-1 expression in EPCs of WT mice, whereas the magnitude of reduction in HO-1 protein expression in EPCs from diabetic CA-AMPK transgenic mice was smaller than in diabetic WT mice. Likewise, incubation of EPCs derived from WT mice with high glucose (25 mmol/L) for 24 hours decreased the protein levels of HO-1 and nuclear factor (erythroid-derived 2)-like 2 (Nrf2, a transcription factor that regulates HO-1 expression). 32 Under both normal and high-glucose conditions, the levels of both HO-1 and Nrf2 proteins in EPCs of CA-AMPK transgenic mice were higher than those in WT mice ( Figure 7B ). SDF-1␣ is a proangiogenic factor that promotes endothelial repair by recruiting EPCs from bone marrow to the injured vessel wall. 28 Consistent with the changes in HO-1 expression, the levels of SDF-1␣ secreted into the culture medium were elevated in EPCs from CA-AMPK transgenic mice compared with those from WT controls ( Figure 7C ). Treatment with high glucose (25 mmol/L) led to a significant reduction of SDF-1␣ secretion in EPCs derived from WT mice, but SDF-1␣ levels in high-glucose-treated EPCs derived from CA-AMPK transgenic mice remained higher than those in WT mice. Treatment of the cells with the HO-1 inhibitor ZnPPIX (zinc protoporphyrin IX; 10 mol/L, 24 hours) abolished the AMPK-dependent elevation of SDF-1␣ secretion in EPCs ( Figure 7C ). Likewise, serum SDF-1␣ levels as measured on the third day after recovery from carotid injury were elevated in CA-AMPK transgenic mice compared with WT littermates under both healthy and diabetic conditions ( Figure 7D ). Figure 6 . Effects of AMP-activated kinase (AMPK) activation on endothelial progenitor cell (EPC) adhesion, migration, tube formation, and superoxide production under healthy and diabetic conditions. EPCs isolated from bone marrow of 12-week-old male constitutively activate AMPK (CA-AMPK) transgenic (Tg) mice or wild-type (WT) controls with or without streptozotocin (STZ)induced diabetes mellitus were labeled with acetylated low-density lipoprotein labeled with DiI (DiI-AcLDL) and then used for analysis of adhesion to human umbilical vein endothelial cells (HUVECs; A), migration in Boyden chamber (B), and tube formation with HUVECs (C). The level of superoxide production in EPCs (D) and carotid arteries (E) isolated from Tg mice and WT littermates under healthy and STZ-induced diabetic conditions was measured. nϭ6 for all WT and Tg groups in panels A, B, and C, and nϭ5 for all groups in panels D and E. Comparisons were made with 2-way ANOVA followed by Bonferroni post hoc tests. *PϽ0.05, **PϽ0.01.
To further evaluate the in vivo significance of HO-1 in modulating EPC function, WT and CA-AMPK transgenic mice were subjected to carotid injury and then treated with vehicle or ZnPPIX (5 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 ). ZnPPIX markedly downregulated serum SDF-1␣ levels in both CA-AMPK transgenic and WT mice ( Figure 7D ). Furthermore, the number of circulating EPCs ( Figure 7E ) and angiogenic cells ( Figure 7F ), reendothelialization of injured carotid arteries (online-only Data Supplement Figure VII) , and incorporation of DiI-labeled EPCs (online-only Data Supplement Figure  VIII) were all decreased after ZnPPIX treatment, which suggests an indispensable role of HO-1 in AMPK-mediated EPC mobilization and endothelial repair.
Discussion
Several antidiabetic and vascular protective agents, including metformin, thiazolidinediones, statins, high-density lipoprotein, and adiponectin, have been shown to prevent diabetic vascular dysfunction possibly by activating AMPK in endothelial cells. 15, 33, 34 However, because of the ubiquitous ex-pression pattern of this kinase, the relative contribution of endothelial AMPK in maintaining vascular homeostasis remains unclear. The present study demonstrates that endothelium-specific activation of AMPK alone is sufficient to protect diabetic mice from endothelial dysfunction caused by vascular injury, without obvious effects on hyperglycemia. This protective effect of AMPK is more evident in injured blood vessels, which suggests that the improved relaxation to the endothelium-dependent vasodilators acetylcholine and UK14304 in CA-AMPK transgenic mice is attributable in part to enhanced endothelial repair.
Previous studies have shown EPCs to be an important contributor to neovascularization, possibly by secretion of angiogenic factors that act in a paracrine manner to support endothelial regeneration. 7, 27 Reduced number and function of EPCs are causally associated with diabetes mellitus-induced impairment in vasculogenesis. 10, 11 The present study demonstrates that the augmented endothelial repair in CA-AMPK transgenic mice is attributable in part to an improved functionality of EPCs, as evidenced by increased mobilization of Figure 7 . AMP-activated kinase (AMPK) increases stromal cell-derived factor (SDF)-1␣ production and EPC mobilization via upregulation of heme oxygenase-1 (HO-1). A, Representative immunoblots (upper panel) and quantification (lower panel) of HO-1 expression in endothelial progenitor cells (EPCs) isolated from bone marrow of 12-week-old constitutively activate AMPK (CA-AMPK) transgenic mice (Tg) and WT controls with or without streptozotocin-induced diabetes mellitus. B, EPCs isolated from Tg mice and WT controls were cultured in a medium containing high glucose (25 mmol/L) or mannitol (25 mmol/L, as osmotic control) for 24 hours, followed by immunoblotting analysis for HO-1 and Nrf2. C, SDF-1␣ concentration in the conditioned medium of bone marrowderived EPCs grown in 25 mmol/L glucose or mannitol controls in the absence or presence of ZnPPIX (10 mol/L). D, Serum SDF-1␣ levels measured on day 3 after CA-AMPK transgenic (Tg) or WT controls with or without streptozotocininduced diabetes mellitus were subjected to carotid denudation in the absence or presence of ZnPPIX (zinc protoporphyrin; 5 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 for 3 days). E and F, Flow cytometric analysis for circulating Flk1 ϩ CD34 ϩ EPCs or circulating CD31 ϩ CXCR4 ϩ angiogenic cells in mice treated without or with ZnPPIX. nϭ5 for all groups in panels A, B, C, and D, and nϭ6 for all groups in panels E and F. Comparisons were made with 2- way  (panels A, B, D, E, and F) EPCs into the circulation and incorporation of EPCs into injured blood vessel wall. This conclusion is also corroborated by our ex vivo findings that EPCs derived from CA-AMPK transgenic mice are resistant to hyperglycemiainduced impairment in adhesion, migration, and tube formation. These observations are consistent with several previous reports that showed that pharmacological activation of AMPK by AICAR (5-amino-1-␤-D-ribofuranosyl-imidazole-4-carboxamide) promotes differentiation of human cord blood-derived EPCs 22 and also rescues the in vitro function of mouse bone marrow-derived EPCs. 21 Furthermore, AMPK activation is implicated in the protective effects of adiponectin against hyperglycemia-induced premature senescence of both human-and mouse-derived EPCs. 23 Therefore, AMPK appears to exert its protective effects against diabetes mellitus-induced impairment in reendothelialization through its pleiotropic actions on almost all the major steps involved in EPC-mediated neovascularization.
Hyperglycemia-induced reactive oxygen species accumulation has been postulated to be a central mediator of diabetes mellitus-induced EPC dysfunction. 35 In both mature endothelial cells and EPCs, AMPK activation by its agonists suppresses high-glucose-induced reactive oxygen species generation by promoting mitochondrial biogenesis, 17 inhibiting NADPH oxidase activity, 36 and inducing the expression of both mitochondrial uncoupling protein 2 37 and manganese superoxide dismutase. 21 Likewise, the present study shows that the improved EPC function in diabetic CA-AMPK transgenic mice is accompanied by a reduction in intracellular reactive oxygen species levels, which suggests that the suppression of oxidative stress represents an important mechanism accounting for the protective effects of AMPK against diabetes mellitus-induced dysfunction of EPCs.
Another notable finding of the present study is the uncovering of heme oxygenase as a downstream target of AMPK that mediates EPC mobilization and subsequent reendothelialization. The enzyme exists as a constitutive isoform (HO-2) and an inducible isoform (HO-1) and catalyzes the degradation of heme into carbon monoxide, iron, and biliverdin, which is further converted to bilirubin by biliverdin reductase. 38, 39 HO-1 is an important regulator of angiogenesis via improving EPC function. 29, 30 EPC-mediated reendothelialization and neovascularization during wound healing are impaired in HO-1 knockout mice 40 or by pharmacological inhibitors of HO-1 but are augmented by pharmacological inducers of HO-1 or adenovirus-mediated gene transfer of HO-1 in both rodents and rabbits. 29, 35, 41 The enzyme appears to play an indispensable role in several steps of EPCmediated vascular repair, including the growth, maturation, and mobilization of bone marrow EPCs, as well as the migration, recruitment, and adhesion of EPCs to sites of injury. 28, 30 In human endothelial cells, AMPK agonists stimulate HO-1 gene expression via induction of Nrf2. 31 The present study demonstrates an increased protein expression of both HO-1 and its transcriptional activator, Nrf2, 31, 32 in EPCs isolated from CA-AMPK transgenic mice. Furthermore, AMPK-dependent mobilization of EPCs into circulation and reendothelialization were abrogated by the in vivo administration of ZnPPIX, an inhibitor of heme oxygenase activity.
In addition, the expression of both HO-1 and Nrf2 was decreased in EPCs isolated from streptozotocin-induced diabetic mice and in EPCs cultured in high-glucose medium. AMPK activity is also decreased in EPCs from streptozotocininduced diabetic mice. 21 Taken together, these findings suggest that a diminished AMPK-Nrf2-HO-1 signaling cascade in EPCs may account in part for impaired reendothelialization in diabetes mellitus. Although the present study shows HO-1 as a downstream target of AMPK, it is noteworthy that in vivo administration of HO-1 inducers has been shown to induce AMPK activation in different tissues, possibly by increasing adiponectin production. 42, 43 Whether a positive feedback regulation between AMPK and HO-1 exists in EPCs and contributes to neovascularization warrants further investigation.
The beneficial effects of HO-1 on EPC function and vascular repair are mediated by its 3 by-products via multiple mechanisms. 30 In particular, carbon monoxide promotes reendothelialization after vascular injury by enhancing the proliferation, mobilization, migration, and differentiation of EPCs. 44 The antioxidant activity of bilirubin may also contribute to the protective effects of HO-1 against hyperglycemia-induced EPC dysfunction by reducing intracellular reactive oxygen species. 38 Furthermore, HO-1 enhances the production and actions of VEGF and SDF-1␣. 40, 41 On the other hand, both VEGF and SDF-1␣ have been shown to induce HO-1 expression in endothelial cells. 40 HO-1mediated neovascularization is abrogated by blockade of VEGF and SDF-1␣ with neutralizing antibodies to these 2 factors, which suggests that HO-1 acts as both an upstream regulator and a downstream mediator of VEGF and SDF-1␣. 41 Figure 8 . A proposed mechanism by which AMP-activated kinase (AMPK) activation improves vascular reactivity through induction of heme oxygenase-1 (HO-1) and suppression of reactive oxygen species (ROS) in both endothelial progenitor cells (EPCs) and endothelial cells. AMPK induces HO-1 via the transcription factor Nrf2, which leads to the production of carbon monoxide (CO). AMPK also increases the production of stromal cell-derived factor (SDF)-1␣, which is also mediated by HO-1. The other by-product of HO-1, bilirubin, may oppose the increase in ROS, which is also downregulated by AMPKmediated stimulation of mitochondrial uncoupling protein (UCP)-2 and manganese superoxide dismutase (MnSOD). This decrease in ROS, together with the increase in CO and SDF-1␣ mediated by AMPK/HO-1, enhances reendothelialization by augmenting the function of EPCs. Furthermore, AMPK/HO1 activation protects endothelial cells from ROS-induced damage, thereby leading to improved vascular reactivity.
Noticeably, reduced SDF-1␣ production has been implicated as a contributor to impaired reendothelialization in mice with streptozotocin-induced diabetes mellitus. 45 In the present study, we found that CA-AMPK transgenic mice were resistant to diabetes mellitus-induced reduction in SDF-1␣ secretion in EPCs and serum SDF-1␣ levels, whereas these effects of AMPK activation were abrogated by pharmacological inhibition of HO-1, which indicates that induction of SDF-1␣ via HO-1 may also contribute to AMPK-mediated EPC mobilization and reendothelialization.
Although the present study focused on the effects of AMPK/HO-1 on EPCs, AMPK/HO-1 actions in endothelial cells are equally important in maintaining endothelial integrity and vascular homeostasis. Activation of both AMPK and HO-1 promotes proliferation and survival of endothelial cells and protects them from oxidative stress-induced apoptosis. 15, 31 Therefore, the improved vascular function in CA-AMPK transgenic mice is attributable to the salutary effects of AMPK in both endothelial cells and EPCs, in part by suppression of oxidative stress and induction of HO-1 ( Figure  8 ). Taken together, these findings suggest that therapeutic interventions to enhance endothelial AMPK activity may represent an attractive modality to prevent vascular complications in diabetes mellitus.
